Journal of the ICRU Vol 13 No 1–2 (2013) Report 89
Oxford University Press

doi:10.1093/jicru/ndw027

Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix

Preface 1

Abstract 3

Acknowledgements 5

1. Introduction 7
- **1.1 Developments in Epidemiology and Treatment of Cervical Cancer** 7
- **1.2 Outline of Report** 8
  - **1.2.1 Prevention, Diagnosis, Prognosis, Treatment, and Outcome** 8
  - **1.2.2 Brachytherapy Techniques and Systems** 8
  - **1.2.3 Brachytherapy Imaging for Treatment Planning** 8
  - **1.2.4 Tumor and Target Volumes and Adaptive Radiotherapy** 9
  - **1.2.5 OAR- and Morbidity-Related Concepts and Volumes** 10
  - **1.2.6 Radiobiological Considerations** 10
  - **1.2.7 Dose and Volume Parameters** 10
  - **1.2.8 Physics Aspects of Three-Dimensional Volumetric Dose Assessment** 10
  - **1.2.9 Radiographic Localization of Absorbed-Dose Points** 10
  - **1.2.10 Sources and Dose Calculation** 11
  - **1.2.11 Treatment Planning** 11
  - **1.2.12 Summary of the Recommendations** 11
  - **1.2.13 Clinical Examples** 12
  - **1.2.14 Electronic Spreadsheet** 12
  - **1.2.15 Report Organization: Summaries, Recommendations, and Key Messages** 12

2. Prevention, Diagnosis, Prognosis, Treatment, and Outcome 13
- **2.1 Etiology and Screening** 13
- **2.2 Patterns of Spread** 13
- **2.3 FIGO Staging and TNM Classification** 13
- **2.4 Tumor and Lymph-Node Imaging** 13
  - **2.4.1 Tumor Assessment** 14
  - **2.4.2 Nodal Assessments by Imaging** 14
- **2.5 Invasive Lymph-Node Assessment** 15
  - **2.5.1 Extra-Peritoneal Laparoscopic Para-Aortic Node Staging** 15
  - **2.5.2 Sentinel Lymph-Node Mapping in Early-Stage Cervical Cancer** 15
  - **2.5.3 Bulky Lymph Nodes** 15
- **2.6 Prognostic Factors** 15
- **2.7 Stage- and Risk-Adapted Multidisciplinary Treatment** 16
  - **2.7.1 FIGO Stage IA1** 16
  - **2.7.2 FIGO Stage IA2** 16
  - **2.7.3 FIGO Stage IB1** 16
  - **2.7.4 FIGO Stage IB2-IVA** 17

2.8 Radiation Therapy 17
2.9 Treatment Results 18
2.9.1 Stage IA 18
2.9.2 Stages IB1 and Limited IIA 18
2.9.3 Stage IB2, Extensive IIA, IIB, III, and IVA 18
2.10 Conclusion 19
2.11 Summary 19
2.12 Key Messages 19

3. Brachytherapy Techniques and Systems 21
3.1 The Evolution of Brachytherapy Systems, Techniques, and Absorbed-Dose Rates Applied to Cervical Center 21
3.2 Historical Radium Systems 22
3.2.1 The Stockholm System 22
3.2.2 The Paris Method 22
3.2.3 The Manchester System 22
3.2.4 The Fletcher (M.D. Anderson) System 24
3.3 From Radium to Man-Made Radionuclides 25
3.4 Contemporary Techniques and the Decline of the Radium Systems 26
3.4.1 Tandem and Ring Techniques (Modified Stockholm Technique) 26
3.4.2 Tandem and Ovoid Techniques (Modified Manchester Technique) 26
3.4.3 Tandem and Ovoid Techniques (Modified Fletcher Technique) 27
3.4.4 The Tandem and Cylinder Technique 27
3.4.5 The Tandem and Mold Technique 28
3.5 Limitations of Historical and Current Brachytherapy Systems, Techniques, and Prescriptions 28
3.5.1 Applications Based on Amount of Radium 28
3.5.2 Application Based on Dose Points (Point A, Point B, Lymph Nodes, Bony Structures, Organs at Risk) 28
3.5.2.1 Ovoid Surface Visibility on Radiographs 29
3.5.2.2 Steep Absorbed-Dose Gradient 29
3.5.2.3 Point A and Tumor Absorbed Dose (According to the Definition Given in this Report) 29
3.5.2.4 Point B and Lymph-Node Absorbed Dose 29
3.5.3 Further Developments Based on TRAK, Points, and Volumes 29
3.5.4 Developments in regard to New Absorbed-Dose Rates 30
3.6 Modern Applications in the Volume-Based Imaging Era with HDR and PDR Brachytherapy 30
3.6.1 Quality of an Application 31
3.6.2 Tandem and Ovoids 31
3.6.3 Tandem and Ring 31
3.6.4 Tandem and Mold 31
3.6.5 Tandem and Cylinder 31
3.6.6 Interstitial Applicators with and without a Tandem and Colpostats 32
3.6.7 Insertion and Planning Techniques based on Volumetric Imaging 33
3.7 External-Beam Radiotherapy 34
3.8 Concluding Remarks 34
3.9 Summary 34
3.10 Key Messages 35

4. Brachytherapy Imaging for Treatment Planning 37
4.1 Clinical Gynecologic Examination and Clinical Diagrams 37
4.2 Magnetic Resonance Imaging 37
4.3 Computed Tomography 38
4.4 Positron-Emission Tomography (PET-CT) 39
4.5 Ultrasound 40
4.6 Radiography 41
4.7 Imaging in Treatment Planning 43
4.7.1 Imaging in external-beam radiotherapy 43
4.7.2 Imaging in brachytherapy 43
4.8 Summary 45
4.9 Key Messages 46

5. Tumor and Target Volumes and Adaptive Radiotherapy 49
5.1 Introduction and Overview 49
5.2 Volume Definitions in Adaptive (Gynecological) Radiotherapy 49
5.2.1 Tumor and Target Volume Definitions for the Primary Tumor 50
5.2.1.1 GTV for the Primary Tumor (GTV-T) 50
5.2.1.2 CTV for the Primary Tumor (CTV-T) 50
5.2.1.3 Residual GTV-T (GTV-T_{res}) 50
5.2.1.4 Adaptive CTV-T (CTV-T_{adapt}) 50
5.2.1.5 High-Risk CTV-T (CTV-T_{HR}) 50
5.2.1.6 Intermediate-Risk CTV-T (CTV-T_{IR}) 50
5.2.1.7 Low-Risk CTV-T (CTV-T_{LR}) 50
5.2.1.8 Planning Target Volume (PTV-T) 50
5.2.1.9 Initial Treatment Based on Different CTV-Ts 51
5.2.2 Target Volume Definitions for Nodal and Metastatic Disease 51
5.3 Clinical Aspects of Selecting and Contouring the Initial (GTV-T_{init}) and Residual (GTV-T_{res}) GTV-T 51
5.3.1 Concept of the GTV 51
5.3.2 GTV-T Selection and Delineation 51
5.3.2.1 GTV-T Selection and Investigation Technique 51
5.3.2.2 Identification of Sub-GTV-T(s) 52
5.3.2.3 The Composite GTV: The GTV-T 54
5.3.3 Change of Primary Tumors during Treatment: The Initial GTV-T (GTV-T_{init}) and the Residual GTV-T (GTV-T_{res}) 54
5.3.4 Initial GTV-T (GTV-T_{init}) and Residual GTV-T (GTV-T_{res}) in Cervical Cancer Radiotherapy (at the Time of Brachytherapy) 54
5.3.4.1 Initial GTV (GTV-T_{init}) 55
5.3.4.2 Residual GTV (GTV-T_{res}) 55
5.3.5 Uncertainties in GTV-T Selection and Contouring 56
5.4 CTV and Adaptive CTV 58
5.4.1 Concept of CTV 58
5.4.2 CTV-T Selection and Delineation 58
5.4.3 Change of Primary Tumor CTV-T during Treatment: The Adaptive CTV 59
5.4.4 Initial CTV-T and Adaptive CTV-T in Stage-Related Treatment of Cervical Cancer 60
5.4.4.1 Uterine Cervix: The Primary CTV-T for any Invasive Cervical Cancer 61
5.4.4.2 Peri-Cervical Areas at Risk in Tumors with an Intact Cervix (Stage IB) 61
5.4.4.3 Peri-Cervical Areas at Risk in Tumors Infiltrating beyond the Cervix (Stage II-IVA) 64
5.4.4.4 Regional Lymph Nodes Involved and at Risk 64
5.4.5 High-Risk CTV (CTV_{HR}), Intermediate-Risk CTV (CTV_{IR}), Low-Risk CTV (CTV_{LR}) in Combined Radiotherapy of Cervical Cancer 65
5.4.5.1 The High-Risk CTV-T: The Adaptive CTV-T for Cervical Cancer Brachytherapy 67
5.4.5.1.1 Alternative Imaging Modalities for Selection of CTV_{HR} 67
5.4.5.2 The Intermediate-Risk CTV-T (CTV-T_{IR}) 68

5.4.5.2.1 Selection of the CTV-T_{IR} for Various Patterns of Tumor Response after EBRT ± Chemotherapy 69
5.4.6 Uncertainties in Target Selection and Contouring 70
5.5 Planning Target Volume (PTV-T) 73
5.5.1 Concept of PTV-T 73
5.5.2 Geometric Uncertainties in EBRT and Brachytherapy 73
5.5.3 Geometric Uncertainties and PTV Margins in Brachytherapy 73
5.5.4 Internal Margin and the ITV 74
5.5.4.1 External Beam Radiotherapy 74
5.5.4.2 Brachytherapy 74
5.5.5 Set-up Margin (External Margin) 74
5.5.5.1 External Beam Radiotherapy 75
5.5.5.2 Brachytherapy 75
5.5.6 Preimplantation PTV 75
5.6 Recommendations 76
5.7 Summary 77

6. Organs At Risk and Morbidity-Related Concepts and Volumes 79
6.1 Treatment-Related Morbidity and Health-Related Quality of Life 79
6.2 Radiation-Related Morbidity Endpoints 80
6.3 Volume Selection and Contouring Uncertainties for the OAR in Brachytherapy 82
6.4 Geometrical Uncertainties in OAR Assessment 85
6.5 Remaining Volumes at Risk 86
6.6 Recommendations on Morbidity-Related Volumes and Points 87
6.7 Summary 87

7. Radiobiological Considerations 89
7.1 Introduction 89
7.1.1 Dose Distributions 89
7.1.2 Time–Dose Patterns 89
7.2 Time–Dose Patterns: Definitions 90
7.2.1 Application 90
7.2.2 Fraction 90
7.2.3 Fractionated Irradiation 90
7.2.4 Pulse 90
7.2.5 Hypofractionation 90
7.2.6 Hyperfractionation 90
7.2.7 Accelerated Fractionation 91
7.2.8 Fractionated HDR Irradiation 91
7.2.9 PDR Irradiation 91
7.2.10 Continuous LDR Irradiation 91
7.2.11 Non-Continuous LDR 91
7.2.12 Overall Treatment Time 91
7.2.13 Mean Dose Rate 91
7.3 Dose-Rate Effects on Recovery 91
7.3.1 Low-Dose-Rate Brachytherapy 91
7.3.2 Medium-Dose-Rate Brachytherapy 92
7.3.3 High-Dose-Rate Brachytherapy 92
7.4 Other Time-Dose Pattern-Related Radiobiological Processes 92
7.4.1 Repopulation 92
7.4.2 Reoxygenation 93
7.4.3 Redistribution 93
7.5 Dose-Time Patterns and Dose Rates 93
7.6 Radiobiological Consequences of Different Dose–Time Patterns 93
7.6.1 From Absorbed Dose to Biologically Equieffective Dose 93
7.6.2 Mathematical Modeling of the Effects of Dose Rate and Dose per Fraction, Recovery Capacity, and Half-Time of Recovery 94
7.6.2.1 HDR Irradiation 94
7.6.2.2 LDR Irradiation 95
7.6.2.3 PDR Irradiation 96
7.6.3 The Equieffective Absorbed Dose Concept, EQDX 96
7.6.4 Equieffective Dose and EQD2 99
7.6.5 Combination of EBRT and brachytherapy 100
7.7 Recommended Common Terminology for Reporting Dose–Time Parameters of Combined EBRT and ICBT 100
7.8 Uncertainties Related to the Dose–Time Modeling 102
7.9 Equivalent Uniform Dose, EUD 102
7.10 Recommendations for Reporting Dose–Time Parameters 103
7.11 Summary 103

8. Dose and Volume Parameters for Prescribing, Recording, and Reporting Brachytherapy, Alone and Combined with External-Beam Radiotherapy 105
8.1 Brief Historical Survey of Dose Effects and Reporting 105
8.2 Dose Distribution and DVH for Targets and OARs 105
8.3 Point Doses and Dose–Volume Parameters for the Target 108
8.3.1 TRAK and Dose to Point A 108
8.3.2 CTV_{HR} and CTV_{IR} ($D_{98\ \%}$, $D_{90\ \%}$, $D_{50\ \%}$) 108
8.3.3 GTV_{res} at Time of Brachytherapy ($D_{98\ \%}$) 109
8.3.4 PTV for Brachytherapy 109
8.3.5 Lymph Nodes ($D_{98\ \%}$) 110
8.4 OAR: Dose–Point and Dose–Volume Parameters 110
8.4.1 Bladder, Rectum, Sigmoid, and Bowel: High Dose Regions, Points, and Small Volumes ($D_{0.1\ cm^3}$, $D_{2\ cm^3}$) 111
8.4.2 Bladder, Rectum, Sigmoid, and Bowel: Intermediate- and Low-Dose and Non-Small Volumes 113
8.4.3 Vagina High-, Intermediate-, and Low-Dose Regions, Points, Small and Large Volumes 115
8.4.4 Other OAR 116
8.5 Specific Issues in Dose–Volume Reporting for the Combination of EBRT and Brachytherapy 116
8.6 From Planning Aims to Prescription 119
8.6.1 Traditional Terms for Dose Prescription 119
8.6.2 Concepts and Terms: From Planning Aim to Dose Prescription 119
8.7 Isodose Surface Volume 120
8.8 Recommendations for Reporting 120
8.9 Summary 121

9. Volumetric Dose Assessment 123
9.1 Applicator Reconstruction 123
9.2 Definition of Reference Points in 3D Images 124
9.3 Registration and Fusion of Images 125
9.3.1 Registration According to the Brachytherapy Applicator 125
9.3.2 Image Fusion for Reconstruction Purposes 126
9.3.3 Fusion of Pre-EBRT and Brachytherapy Planning Images 126
9.3.4 Fusion of Target Contours between Image Series at the Time of Brachytherapy 127
9.4 Volume Reconstruction, Voxel Size, and DVH Calculation 127
9.5 Intra-Fraction, Inter-Fraction, and Inter-Application Variations 128
9.5.1 Intra- and Inter-Fraction Variations 129
9.5.2 Inter-Application Uncertainties 129

9.5.3 Summation of Dose Across Treatment Applications 129
9.6 Key Messages 130
9.7 Summary 130

10. Radiographic Dose Assessment 133
10.1 Target Points 133
10.1.1 Location of Point A 133
10.1.2 Relationship between point A dose and the CTV_{HR} $D_{90\ \%}$ 134
10.1.3 Isodose-surface volumes and dimensions 134
10.1.4 Target dose approximation 134
10.1.5 Lymph-node and Pelvic-wall points 135
10.1.5.1 Pelvic wall reference points 137
10.1.5.2 Lymphatic trapezoid 137
10.2 Reference Points for Upper, Mid, and Low Vagina 137
10.3 Reference Points for Rectum and Bladder 138
10.3.1 Recto-vaginal reference point 138
10.3.2 Bladder reference point 139
10.3.3 Clinical relevance of the bladder and rectal reference points 139
10.3.4 Sigmoid reference point 140
10.4 Uncertainties with Radiographic Localization 140
10.5 Recommendations for Reporting 141
10.6 Summary 141

11. Sources and Absorbed-Dose Calculation 143
11.1 Radionuclides 143
11.2 Source-Strength Specification 143
11.2.1 Reference Air-Kerma Rate 143
11.2.1.1 Definition of RAKR 143
11.2.1.2 Analogs 143
11.2.1.3 Measurement 143
11.2.1.4 The Energy Cutoff, δ 144
11.2.1.5 Standards Work in Progress 145
11.2.2 Survey of Previously Used Source-Strength Descriptors 145
11.2.2.1 Radium Mass 145
11.2.2.2 The Milligram-Radium Equivalent 145
11.2.2.3 Contained, Apparent, and Equivalent Activity 145
11.2.2.4 Exposure Rate at 1 m 145
11.2.3 Advantages of RAKR 146
11.2.4 The Air-Kerma-Rate Constant, Γ_δ 146
11.3 Total Reference Air Kerma 146
11.4 Absorbed-Dose Calculation 147
11.4.1 Absorbed-dose-calculation formalism 147
11.4.2 Inhomogeneity Correction and Applicator Influences on the Absorbed Dose 148
11.5 Recommendations for Reporting 149
11.6 Summary 149

12. Treatment Planning 151
12.1 Combining EBRT and Brachytherapy: Dose and Fractionation Strategies 152
12.2 Implant Geometry 154
12.2.1 Applicator type 154
12.2.2 Pre-planning of the implant 155
12.3 Loading Pattern and 3D Absorbed-Dose Distribution without Reference to Targets 155
12.4 Optimization of the Dose Distribution 157
12.4.1 General aspects of dose optimization 157
12.4.2 Forward planning 158

12.4.3 Inverse planning 158
12.4.4 Optimization by changing absorbed-dose rate in LDR and PDR treatments or fraction size in HDR brachytherapy 159
12.5 Key Messages 159
12.6 Summary 159

13. Summary of the Recommendations 161
Level 1 - Minimum standard for reporting 161
Level 2 - Advanced standard for reporting 161
Level 3 - Research-oriented reporting 162

Appendix A Examples
A.1 Case 1: Small Cervical Cancer Stage IB1, with Positive Nodes,Treated with 3D Conformal EBRT and Concomitant Chemotherapy Plus Conformal Boost and MRI-Based PDR Brachytherapy with Mould Technique 165
A.1.1 General Patient Information 165
A.1.2 Tumor Extension at Diagnosis 165
A.1.2.1 Gynecological Examination (Figure A.1.1, Table A.1.1) 165
A.1.2.2 MRI of the pelvic and Para-Aortic Area (Figure A.1.1, Table A.1.1) 165
A.1.2.3 Other Findings 165
A.1.2.4 Conclusion 165
A.1.3 Treatment Intention 165
A.1.4 External Beam Radotherapy 166
A.1.5 Brachytherapy 167
A.1.5.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.1.4) 167
A.1.5.2 MRI of the Lower Pelvic Area at First Brachytherapy (Figure A.1.4) 168
A.1.5.3 Treatment Planning Aim 168
A.1.5.4 Treatment Delivery 168
A.1.5.5 Equipment Used for Brachytherapy (Figure A.1.5) 168
A.1.6 Treatment Planning and Reporting Brachytherapy and EBRT 170
A.1.6.1 Example of Dose Distribution 170
A.1.7 Current Patient Status 170
A.2 Case 2: Large Cervical Cancer Stage IB2, Intracavitary, No Nodes, Treated with 3D Conformal Box EBRT and Parametrial Boost, with Concomitant Chemotherapy, and MRI-Based Intracavitary Tandem/Ring and Tandem/Ovoid HDR Brachytherapy 171
A.2.1 General Patient Information 171
A.2.2 Tumor Extension at Diagnosis 171
A.2.2.1 Gynecological Examination (Figure A.2.1, Table A.2.1) 171
A.2.2.2 MRI of the Lower Pelvic Area (Figure A.2.1, Table A.2.1) 171
A.2.2.3 Other Findings 171
A.2.2.4 Conclusion 171
A.2.3 Treatment Intention 171
A.2.4 External Beam Radiotherapy 171
A.2.5 Brachytherapy 173
A.2.5.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.2.4) 173
A.2.5.2 MRI of the Lower Pelvic Area at First Brachytherapy (Figure A.2.4) 174
A.2.5.3 Treatment Planning Aim 174
A.2.5.4 Treatment Delivery 175
A.2.5.5 Equipment Used for Brachytherapy (Figure A.2.5) 175
A.2.6 Treatment Planning and Reporting Brachytherapy and EBRT 175

A.2.6.1 Example of Absorbed Dose Distribution 177
A.2.7 Current Patient Status 177
A.3 Case 3: Large Cervical Cancer Stage IIA2, No Nodes, Treated with 3D Conformal EBRT, with Concomitant Chemotherapy, and MRI-Based Intracavitary Tandem/Ovoid PDR Brachytherapy 179
A.3.1 General Patient Information 179
A.3.2 Tumor Extension at Diagnosis 179
A.3.2.1 Gynecological Examination (Figure A.3.1, Table A.3.1) 179
A.3.2.2 MRI of the Lower Pelvic Area (Figure A.3.1, Table A.3.1) 179
A.3.2.3 Other Findings 179
A.3.2.4 Conclusion 179
A.3.2.5 Treatment Intention 179
A.3.3 External Beam Radiotherapy 179
A.3.4 Brachytherapy 180
A.3.4.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.3.4) 180
A.3.4.2 MRI of the Lower Pelvic Area at First Brachytherapy (Figure A.3.5) 180
A.3.4.3 Treatment Planning Aim 181
A.3.4.4 Treatment Delivery 183
A.3.4.5 Equipment Used for Brachytherapy (Figure A.3.5) 183
A.3.4.6 Treatment Reporting 183
A.3.4.7 Example of Dose Distribution 184
A.3.5 Current Patient Status 184
A.4 Case 4: Cervical Cancer Stage IB1 Treated with 3D Conformal External Beam Irradiation, Concomitant Chemotherapy, and Radiograph-Based Intracavitary Tandem/Ovoid High Dose Rate Brachytherapy 185
A.4.1 General Patient Information 185
A.4.2 Tumor Extension at Diagnosis 185
A.4.2.1 Gynecological examination (Figure A.4.1, Table A.4.1) 185
A.4.2.2 MRI of the Pelvis (Figure A.4.1, Table A.4.1) 185
A.4.2.3 Other Findings 185
A.4.2.4 Conclusion 185
A.4.3 Treatment Intention 185
A.4.4 External Beam Radiotherapy (Figures A.4.3 and Table A.4.2) 185
A.4.5 Brachytherapy 187
A.4.5.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.4.4, Table A.4.1) 187
A.4.5.2 Treatment Planning Aim 187
A.4.5.3 Treatment Delivery 188
A.4.5.4 Equipment Used for Brachytherapy (Table A.4.4, Figure A.4.5) 188
A.4.6 Treatment Planning and Reporting EBRT and Brachytherapy 190
A.4.6.1 Example of Dose Distribution (Figure A.4.6) 191
A.4.7 Current Patient Status 191
A.5 Case 5: Large Cervical Cancer Stage IIB with Vaginal Involvement, No Nodes, Treated with 3D Conformal EBRT with Concomitant Chemotherapy, and MRI Based Intracavitary and Interstitial HDR Brachytherapy Using a Tandem/Ring Applicator with Needles 193
A.5.1 General Patient Information 193
A.5.2 Tumor Extension at Diagnosis 193
A.5.2.1 Gynecological Examination (Figure A.5.1, Table A.5.1) 193
A.5.2.2 MRI of the Lower Pelvic Area (Figure A.5.1, Table A.5.1) 193
A.5.2.3 Other Findings 193
A.5.2.4 Conclusion 193
A.5.3 Treatment Intention 193
A.5.4 External Beam Radiotherapy (Figure A.5.3, Table A.5.2) 193
A.5.5 Brachytherapy 195
A.5.5.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.5.4, Table A.5.1) 195
A.5.5.2 MRI of the Lower Pelvic Area at First Brachytherapy (Figure A.5.4,Table A.5.1) 195
A.5.5.3 Treatment Planning Aim 195
A.5.5.4 Treatment Delivery 196
A.5.5.5 Equipment Used for Brachytherapy (Figure A.5.5) 196
A.5.6 Treatment Planning and Reporting Brachytherapy and EBRT 197
A.5.6.1 Example of Dose Distribution 199
A.5.7 Current patient status 199
A.6 Case 6: Large Cervical Cancer Stage IIIB with Pathological Pelvic Nodes Treated with IMRT, Concomitant Chemotherapy, and MRI Based Intracavitary and Interstitial Tandem/Ring Pulsed Dose Rate Brachytherapy with Needles 201
A.6.1 General Patient Information 201
A.6.2 Tumor Extension at Diagnosis 201
A.6.2.1 Gynecological Examination (Figure A.6.1, Table A.6.1) 201
A.6.2.2 MRI of the Pelvis (Figure A.6.1, Table A.6.1) 201
A.6.2.3 Other Findings 201
A.6.2.4 Conclusion 201
A.6.3 Treatment Intention and Overall Treatment Plan 201
A.6.4 External Beam Radiotherapy (Figure A.6.3 and Table A.6.2) 201
A.6.5 Brachytherapy 205
A.6.5.1 Gynecological Examination at First Time of Brachytherapy (Figure A.6.4) 205
A.6.5.2 MRI of the Pelvis at First Brachytherapy (Figure A.6.4 andTable A.6.1) 206
A.6.5.3 Treatment Planning aim (Table A.6.3) 206
A.6.5.4 Treatment Delivery 206
A.6.5.5 Equipment Used for Brachytherapy (Table A.6.4 and Figure A.6.5a and Figure A.6.5b and Figure A.6.5) 207
A.6.6 Treatment Planning and Reporting Brachytherapy and EBRT 207
A.6.6.1 Example of Dose Distribution (Figure A.6.6) 207
A.6.7 Current Status 207
A.7 Case 7: Large Cervical Cancer Stage IIB, with 3D Conformal EBRT with Concomitant Chemotherapy, and Radiograph-Based Intracavitary PDR Brachytherapy with Mould Technique 209
A.7.1 General Patient Information 209
A.7.2 Tumor Extension at Diagnosis 209
A.7.2.1 Gynecological Examination (Figure A.7.1 and Table A.7.1) 209
A.7.2.2 MRI of the Lower Pelvic Area (Figure A.7.1, Table A.7.1) 209
A.7.2.3 Other Findings 209
A.7.2.4 Conclusion 209
A.7.3 Treatment intention 209
A.7.4 External Beam Radiotherapy 209
A.7.5 Brachytherapy 211
A.7.5.1 Gynecological Examination at the First Time of Brachytherapy (Figure A.7.4) 211
A.7.5.2 Treatment Planning Aim 212
A.7.5.3 Treatment Delivery 212
A.7.5.4 Equipment Used for Brachytherapy (Figure A.7.5) 212
A.7.6 Treatment Planning and Reporting Brachytherapy and EBRT 213
A.7.6.1 Example of Dose Distribution 213
A.7.7 Current Patient Status 215

A.8 Case 8: Large Cervical Cancer Stage IIIB with No Nodes, Treated with 3D Conformal Box with Concomitant Chemotherapy and MRI-Based Intracavitary and Interstitial HDR Brachytherapy with Tandem/Ring Applicator and Needles .. 217
A.8.1 General Patient Information 217
A.8.2 Tumor Extension at Diagnosis 217
A.8.2.1 Gynecological Examination (Figure A.8.1, Table A.8.1) 217
A.8.2.2 MRI of the Pelvis (Figure A.8.1, Table A.8.1) 217
A.8.2.3 Other Findings 217
A.8.2.4 Conclusion 217
A.8.3 Treatment Intention 217
A.8.4 External Beam Radiotherapy 217
A.8.5 Brachytherapy 220
A.8.5.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.8.4) 220
A.8.5.2 MRI of the Lower Pelvic Area at First Brachytherapy (Figure A.8.4) 220
A.8.5.3 Treatment Planning Aim 220
A.8.5.4 Treatment Delivery 220
A.8.5.5 Equipment Used for Brachytherapy (Figure A.8.5) 221
A.8.6 Treatment Planning and Reporting Brachytherapy and EBRT 222
A.8.6.1 Example of Dose Distribution 224
A.8.7 Current Patient Status (Figure 8.7) 224
A.9 Case 9: Cervical Cancer Stage IIA2 Treated with 3D Conformal External-Beam Irradiation, Concomitant Chemotherapy, and Radiograph-Based Intracavitary Low Dose-Rate Brachytherapy with Tandem and Ovoids 225
A.9.1 General Patient Information 225
A.9.2 Tumor Extension at Diagnosis 225
A.9.2.1 Gynecological Examination (Figure A.9.1, Table A.9.1) 225
A.9.2.2 CT of the Pelvis (Figure A.9.1, Table A.9.1) 225
A.9.2.3 Other Findings 225
A.9.2.4 Conclusion 225
A.9.3 Treatment Intention 225
A.9.4 External Beam Radiotherapy (Figure A.9.3 and Table A.9.2) 225
A.9.5 Brachytherapy 228
A.9.5.1 Gynecological Examination at the Time of First Brachytherapy (Figure A.9.4, Table A.9.1) 228
A.9.5.2 Treatment Planning Aim 228
A.9.5.3 Treatment Delivery 228
A.9.5.4 Equipment Used for Brachytherapy (Table A.9.4, Figure A.9.5) 229
A.9.6 Treatment Planning and Reporting EBRT and Brachytherapy 229
A.9.7 Current Patient Status 229

References 234